{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:29:06Z","timestamp":1776407346761,"version":"3.51.2"},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T00:00:00Z","timestamp":1500854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate efficacy of sulfasalazine for axial ankylosing spondylosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>67 patients fulfilling the inclusion criteria were included and randomized into treatment and placebo group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean age in treatment group was 31\u00a0years (range: 17\u201360); placebo group was 30\u00a0years (18\u201346). Mean disease duration treatment group 8.4\u00a0years (range: 3\u201325) and placebo group was 8.3\u00a0years (3\u201319). Clinically significant improvement in <jats:styled-content style=\"fixed-case\">ASDAS<\/jats:styled-content> (\u0394ASDAS\u00a0&gt;\u00a01.1) seen in 15.1% of placebo and 67.7% in treatment group (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.001). The mean\u00a0\u00b1\u00a0SD of \u0394ASDAS in treatment group was 1.33\u00a0\u00b1\u00a00.38 (range: 0.9\u20132.3) where as in placebo group it was 0.748\u00a0\u00b1\u00a00.23 (0.4\u20131.3) with significant difference (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.00). The mean\u00a0\u00b1\u00a0SD of \u0394BASDAI of treatment group was 3.29\u00a0\u00b1\u00a00.97 (range: 1.5\u20135.5) placebo group was 1.47\u00a0\u00b1\u00a00.99(0.5\u20134.5) with <jats:italic>P<\/jats:italic>\u00a0=\u00a00.00. The mean value of \u0394BASMI of drug group 3.29\u00a0\u00b1\u00a00.97(range: 1.8\u20135) and of placebo group was 1.47\u00a0\u00b1\u00a00.99 (0.6\u20133.7) with (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.00). Clinical improvenent in (\u0394ASDAS\u00a0&gt;\u00a01.1) was observed in patients of both the groups with disease duration \u2264\u00a04\u00a0years. However it was significantly higher in treatment group (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.04). Highly significant improvement in (\u0394ASDAS\u00a0&gt;\u00a02) was observed in two of five patients in treatment group with disease duration \u2264\u00a04\u00a0years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Sulfasalazine is effective in axial <jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content> esp. in younger patients (&lt;\u00a025\u00a0years), disease duration &lt;\u00a04\u00a0years at the time of initiation of treatment and high disease activity (BASDAI\u00a0&gt;\u00a07, CRP\u00a0&gt;\u00a050\u00a0mg\/L). This signifies early diagnosis and treatment is very important in management and prevention of disease progression.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.13124","type":"journal-article","created":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T09:42:58Z","timestamp":1500889378000},"page":"308-314","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis"],"prefix":"10.1111","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8821-6652","authenticated-orcid":false,"given":"Shefali","family":"Khanna Sharma","sequence":"first","affiliation":[{"name":"Departments of Internal Medicine Unit of Clinical Immunology and Rheumatology Post\u2010Graduate Institute of Medical Research (PGIMER) Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3418-4541","authenticated-orcid":false,"given":"Vikas","family":"Kadiyala","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine Unit of Clinical Immunology and Rheumatology Post\u2010Graduate Institute of Medical Research (PGIMER) Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gsrsnk","family":"Naidu","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine Unit of Clinical Immunology and Rheumatology Post\u2010Graduate Institute of Medical Research (PGIMER) Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varun","family":"Dhir","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine Unit of Clinical Immunology and Rheumatology Post\u2010Graduate Institute of Medical Research (PGIMER) Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,7,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.11.1074"},{"key":"e_1_2_7_3_1","first-page":"593","article-title":"Peripheral arthritis in ankylosing spondylitis. A review of 209 patients followed up for more than 20\u00a0years","volume":"58","author":"Ginsburg WW","year":"1983","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2009.11.015"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.293.6552.911"},{"key":"e_1_2_7_7_1","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis. The Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310905"},{"key":"e_1_2_7_9_1","first-page":"171","article-title":"Sulphasalazine in the treatment of ankylosing spondylitis [Serbocroatian]","volume":"112","author":"Krajnc I","year":"1990","journal-title":"Lijec Vjesn"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780391209"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/29.1.41"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/32.8.729"},{"key":"e_1_2_7_13_1","first-page":"159","article-title":"Sulphasalazine in ankylosing spondylitis: a prospective, randomized, double\u2010blind, placebo\u2010controlled study and comparison with other controlled studies [German]","volume":"61","author":"Schmidt WA","year":"2002","journal-title":"Z Rheumatol"},{"key":"e_1_2_7_14_1","first-page":"722","article-title":"Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials","volume":"33","author":"Chen J","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283524b82"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000187"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.178"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.13124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T09:28:19Z","timestamp":1695893299000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.13124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,24]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/1756-185X.13124"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.13124","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,24]]},"assertion":[{"value":"2017-07-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}